Search alternatives:
significantly improves » significantly improved (Expand Search), significantly improve (Expand Search), significantly improving (Expand Search)
improves decrease » improves disease (Expand Search), improve disease (Expand Search), improved urease (Expand Search)
level decrease » levels decreased (Expand Search), level increased (Expand Search), teer decrease (Expand Search)
Showing 61 - 80 results of 13,261 for search '(( significant ((level decrease) OR (mean decrease)) ) OR ( significantly improves decrease ))', query time: 0.43s Refine Results
  1. 61
    Kylo-0603’s EC50 & tissue levels.

    Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 62
    FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection.

    FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

    Published 2024
    Save to List
    Saved in:
  3. 63
    EF-24 induces significant transcriptional changes in K-562 cells.

    EF-24 induces significant transcriptional changes in K-562 cells. by Ajeet P. Singh (22298432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 64
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 65
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 66
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 67
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 68
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 69
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 70
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 71
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 72
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 73
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 74
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 75
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 76
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 77
    Participants enrollment.

    Participants enrollment. by Chikondi Maluwa (20660522)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 78
    KAP assessment scores (n = 422).

    KAP assessment scores (n = 422). by Chikondi Maluwa (20660522)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 79
    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
    Save to List
    Saved in:
  20. 80
    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
    Save to List
    Saved in:

Search Tools: